BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16723229)

  • 1. Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.
    Park K; Aplasca A; Du MT; Sun L; Zhu Y; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3927-31. PubMed ID: 16723229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
    Lombart HG; Feyfant E; Joseph-McCarthy D; Huang A; Lovering F; Sun L; Zhu Y; Zeng C; Zhang Y; Levin J
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4333-7. PubMed ID: 17531482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
    Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potent and selective TACE inhibitors via the S1 pocket.
    Condon JS; Joseph-McCarthy D; Levin JI; Lombart HG; Lovering FE; Sun L; Wang W; Xu W; Zhang Y
    Bioorg Med Chem Lett; 2007 Jan; 17(1):34-9. PubMed ID: 17064892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.
    Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Rao BG
    Bioorg Med Chem Lett; 2008 Jan; 18(1):44-8. PubMed ID: 18054488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.
    Govinda Rao B; Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Tian SK; Saunders JO
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2250-3. PubMed ID: 17289381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
    Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sheppeck JE; Gilmore JL; Yang A; Chen XT; Xue CB; Roderick J; Liu RQ; Covington MB; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1413-7. PubMed ID: 17188863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
    Venkatesan AM; Davis JM; Grosu GT; Baker J; Zask A; Levin JI; Ellingboe J; Skotnicki JS; Dijoseph JF; Sung A; Jin G; Xu W; McCarthy DJ; Barone D
    J Med Chem; 2004 Dec; 47(25):6255-69. PubMed ID: 15566296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
    Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
    Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of potent MMP inhibitors into selective TACE inhibitors.
    Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.
    Gilmore JL; King BW; Asakawa N; Harrison K; Tebben A; Sheppeck JE; Liu RQ; Covington M; Duan JJ
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4678-82. PubMed ID: 17576061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biaryl substituted hydantoin compounds as TACE inhibitors.
    Yu W; Tong L; Kim SH; Wong MK; Chen L; Yang DY; Shankar BB; Lavey BJ; Zhou G; Kosinski A; Rizvi R; Li D; Feltz RJ; Piwinski JJ; Rosner KE; Shih NY; Siddiqui MA; Guo Z; Orth P; Shah H; Sun J; Umland S; Lundell DJ; Niu X; Kozlowski JA
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5286-9. PubMed ID: 20663669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
    Becker DP; Villamil CI; Barta TE; Bedell LJ; Boehm TL; Decrescenzo GA; Freskos JN; Getman DP; Hockerman S; Heintz R; Howard SC; Li MH; McDonald JJ; Carron CP; Funckes-Shippy CL; Mehta PP; Munie GE; Swearingen CA
    J Med Chem; 2005 Oct; 48(21):6713-30. PubMed ID: 16220987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
    Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
    J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI; Du MT
    Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.